Ftse Mib
34.625,80
0,83%
DAX
18.772,85
0,50%
S&P 500
5.213,40
-0,01%
NASDAQ
16.312,78
-0,20%
Bitcoin
60.588,58
-3,90%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cara Therapeutics Inc (CARA) Cara Therapeutics Inc (CARA) Notizie

CARA

Cara Therapeutics (CARA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CARA
DataOraFonteTitoloSimboloCompagnia
06/05/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CARACara Therapeutics Inc
06/05/202413:00GlobeNewswire Inc.Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:CARACara Therapeutics Inc
02/04/202413:00GlobeNewswire Inc.Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CARACara Therapeutics Inc
07/03/202413:00GlobeNewswire Inc.Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024NASDAQ:CARACara Therapeutics Inc
06/03/202422:45Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CARACara Therapeutics Inc
04/03/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARACara Therapeutics Inc
04/03/202422:01GlobeNewswire Inc.Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
14/02/202400:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CARACara Therapeutics Inc
12/02/202422:01GlobeNewswire Inc.Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024NASDAQ:CARACara Therapeutics Inc
22/01/202413:00GlobeNewswire Inc.Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026NASDAQ:CARACara Therapeutics Inc
18/12/202313:00GlobeNewswire Inc.Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic DermatitisNASDAQ:CARACara Therapeutics Inc
13/11/202322:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARACara Therapeutics Inc
13/11/202322:01GlobeNewswire Inc.Cara Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
02/11/202312:00GlobeNewswire Inc.Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare RoyaltyNASDAQ:CARACara Therapeutics Inc
23/10/202313:00GlobeNewswire Inc.Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023NASDAQ:CARACara Therapeutics Inc
25/09/202313:00GlobeNewswire Inc.Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsNASDAQ:CARACara Therapeutics Inc
05/09/202313:00GlobeNewswire Inc.Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CARACara Therapeutics Inc
07/08/202322:01GlobeNewswire Inc.Cara Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
04/08/202323:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CARACara Therapeutics Inc
03/08/202313:00GlobeNewswire Inc.Cara Therapeutics Appoints Helen M. Boudreau to Board of DirectorsNASDAQ:CARACara Therapeutics Inc
02/08/202313:00GlobeNewswire Inc.Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceNASDAQ:CARACara Therapeutics Inc
24/07/202313:00GlobeNewswire Inc.Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023NASDAQ:CARACara Therapeutics Inc
27/06/202322:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CARACara Therapeutics Inc
03/06/202300:46PR Newswire (US)Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600NASDAQ:CARACara Therapeutics Inc
02/06/202322:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CARACara Therapeutics Inc
01/06/202313:00GlobeNewswire Inc.Cara Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:CARACara Therapeutics Inc
18/05/202308:00PR Newswire (US)Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusNASDAQ:CARACara Therapeutics Inc
18/05/202308:00GlobeNewswire Inc.Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusNASDAQ:CARACara Therapeutics Inc
15/05/202322:01GlobeNewswire Inc.Cara Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
01/05/202313:00GlobeNewswire Inc.Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023NASDAQ:CARACara Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CARA

La tua Cronologia

EU
0574T
0574T
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network